NCT01594723进行中（未招募）2 期
A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 110
- 试验地点
- 63
- 主要终点
- Percentage of Participants with an Objective Response (Objective Response Rate)
研究概览
简要总结
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Swerdlow et al. 2008) and meet the following additional subtype specific criteria:
- •PV: have failed or is intolerant of standard therapies or refuses to take standard medications
- •ET: have failed or is intolerant of standard therapies or refuses to take standard medications
- •MF (participants with MF must meet at least 1 of the following): have intermediate 1, intermediate 2, or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPPS Plus) for Primary Myelofibrosis (Gangat et al. 2011); or have symptomatic MF with spleen greater than 10 centimeter (cm) below left costal margin; or have post-polycythemic MF; or have post-ET MF
- •All PV, ET, and MF participants must meet the following criteria:
- •o Have a quantifiable level of janus kinase 2 with a valine to phenylalanine substitution at amino acid 617 (JAK2 V617F) mutation. This inclusion criterion will not apply to the subset of participants in Cohorts 10 and 11 that must be negative for the JAK2 V617F mutation
- •Are ≥ 18 years of age
- •Have given written informed consent prior to any study-specific procedures
- •Have adequate organ function, including: Hepatic: Direct bilirubin ≤1.5 times upper limits of normal (ULN), alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5 times ULN; Renal: Serum creatinine ≤1.5 times ULN; Bone Marrow Reserve: Absolute neutrophil count (ANC) ≥1000/microliter (mcL), platelets ≥50,000/mcL for participants with ET or PV and ≥25,000/mcL for participants with MF
- •Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale
- •Have discontinued all previous approved therapies for Myeloproliferative Neoplasms (MPNs), including any chemotherapy, immunomodulating therapy (for example, thalidomide, interferon-alpha), immunosuppressive therapy (for example, corticosteroids >10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin, thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and recovered from the acute effects of therapy. Hydroxyurea used to control blood cell counts is permitted at study entry if the subject has been maintained on a stable dose for at least 4 weeks. Low-dose acetylsalicylic acid (aspirin) is permitted as well
- •Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
- •Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug
- •Females with child-bearing potential must have had a negative urine pregnancy test ≤ 7 days before the first dose of study drug and must also not be breastfeeding
- •Are able to swallow capsules
- •For participants who have undergone recent major surgery, at least 28 days must have elapsed between surgery and study participation and the participant must have achieved, in the opinion of the treating physician, at least a good recovery from the surgical procedure
- •Enrollment into Cohort 12 is limited to MF, PV, or ET participants, regardless of mutational status, who, in addition to all other criteria, have demonstrated intolerance to ruxolitinib, failure of primary response to ruxolitinib, or have demonstrated disease progression while on ruxolitinib
排除标准
- •Are currently enrolled in, or discontinued within the last 14 days from a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •Have a corrected QT (QTc) interval >470 millisecond (msec) using Bazett's formula
- •Have serious preexisting medical conditions that, in the opinion of the investigator would preclude participation in the study (for example a gastrointestinal disorder causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndrome)
- •Are currently being treated with agents that are metabolized by Cytochrome P450 3A4 enzyme (CYP3A4) with a narrow therapeutic margin (for example, alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) or Cytochrome P450 2B6 enzyme (CYP2B6) (for example, cyclophosphamide, ifosfamide, tamoxifen, efavirenz, propofol, methadone, and bupropion)
- •Are currently being treated with warfarin or one of its derivatives which is known to alter levels of protein C or protein S. An exception to this criterion will be allowed for participants with a prior history of Budd-Chiari Syndrome who are being treated with warfarin or one of its derivatives
- •Have received a hematopoietic stem cell transplant
- •Have a second primary malignancy that in the judgment of the Investigator and Sponsor may affect the interpretation of results
- •Have an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required)
- •Have a history of congestive heart failure with New York Heart Association (NYHA) Class >2 (NYHA Class 1 and 2 are eligible), unstable angina, recent myocardial infarction (within 6 months prior to administration of study drug), or documented history of ventricular arrhythmia
研究组 & 干预措施
120 mg LY2784544
Experimental
120 milligram (mg) administered orally once daily for 6 cycles (168 days)
干预措施: 120 mg LY2784544 (Drug)
结局指标
主要结局
Percentage of Participants with an Objective Response (Objective Response Rate)
时间窗: Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 24 Months)
次要结局
- Percentage of Participants with a Molecular Response (Molecular Response Rate)(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Percentage of Participants with Hematological Improvement (Hematological Improvement Rate)(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Change in Spleen Size(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Change in Bone Marrow Fibrosis Grade(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Change in Number of Thrombotic or Hemorrhagic Events(3 Months prior to Study Drug (historic) until PD or Participant Stops Study (Estimated up to 24 Months))
- Change in Number of Phlebotomies and Transfusions(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Duration of Response(Confirmed Response to PD or Death from Any Cause (Estimated up to 24 Months))
- Time to Best Response(Baseline to Confirmed Response (Estimated up to 6 Months))
- Change in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Time to Treatment Failure(Baseline to PD, Death from Any Cause or Participant Stops Study (Estimated up to 24 Months))
- Time to Disease Progression(Baseline to Measured PD (Estimated up to 24 Months))
- Progression Free Survival (PFS)(Baseline to PD or Death from Any Cause (Estimated up to 24 Months))
- Change in Activities of Daily Living (ADL)/ Instrumental Activities of Daily Living (IADL)(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Change in EuroQol - 5 dimensions (EQ-5D) Index Score(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Change in International Prognosis Scoring System Scales (IPSS)(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2784544(Predose up to Day 84)
- PK: Time of Maximal Concentration (Tmax) of LY2784544(Predose up to Day 84)
- Change in Liver Size(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
- Change in 6-item Physician Symptom Assessment(Baseline until PD or Participant Stops Study (Estimated up to 24 Months))
研究者
研究点 (63)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of LY2784544 in patients with blood cancerEUCTR2011-001012-56-DEEli Lilly and Company121
进行中（未招募）
1 期
A Study of LY2784544 in patients with blood cancerEUCTR2011-001012-56-ATEli Lilly and Company188
进行中（未招募）
不适用
A Study of LY2784544 in patients with blood cancerEUCTR2011-001012-56-SEEli Lilly and Company121
进行中（未招募）
不适用
A Study of LY2784544 in Patients with blood cancerMyeloproliferative neoplasms (MPNs), myelofibrosis, essentialthrombocythemia, and polycythemia veraMedDRA version: 15.0Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001012-56-ITELI LILLY AND COMPANY188
进行中（未招募）
不适用
Study with Myeloproliferative NeoplasmsMyeloproliferative NeoplasmsMedDRA version: 14.1Level: HLTClassification code 10028578Term: Myeloproliferative disorders (excl leukaemias)System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-001012-56-ESilly S.A150